Advertisement

High-potency statins increase the risk of acute kidney injury: Evidence from a large population-based study

  • Giovanni Corrao
    Correspondence
    Corresponding author. Dipartimento di Statistica e Metodi Quantitativi, Sezione di Biostatistica, Epidemiologia e Sanità Pubblica, Università degli Studi di Milano-Bicocca, Via Bicocca degli Arcimboldi, 8, Edificio U7, 20126 Milano, Italy. Tel.: +39 02 64485854; fax: +39 02 64485899.
    Affiliations
    Division of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy
    Search for articles by this author
  • Davide Soranna
    Affiliations
    Division of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy
    Search for articles by this author
  • Manuela Casula
    Affiliations
    Centre of Epidemiology and Preventive Pharmacology (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milano, Milan, Italy
    Search for articles by this author
  • Luca Merlino
    Affiliations
    Operative Unit of Territorial Health Services, Region Lombardia, Milan, Italy
    Search for articles by this author
  • Maria Gabriella Porcellini
    Affiliations
    Division of Paediatric Nephrology, Paediatric Hospital “Regina Margherita”, Turin, Italy
    Search for articles by this author
  • Alberico L. Catapano
    Affiliations
    Centre of Epidemiology and Preventive Pharmacology (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milano, Milan, Italy

    IRCSS Multimedica, Milan, Italy
    Search for articles by this author

      Highlights

      • We performed a nested case-control study linking healthcare utilization databases.
      • We studied the effect of the potency of statins on the risk of acute kidney injury.
      • Use of high-potency statins seems to increase the risk of acute kidney injury.
      • Use of low-potency statins was not associated to the risk of acute kidney injury.
      • No evidence was observed increasing follow-up or for chronic kidney disease.

      Abstract

      Objective

      To assess the association between acute kidney injury and exposure to either high-potency statins or low-potency statins.

      Design

      A population-based, nested case-control study was performed on a cohort of 316,449 patients from Lombardy (Italy) newly treated with statins between 2007 and 2010 aged 40 years or older. 458 patients experienced acute kidney injury within six months after initial statin prescription. Up to four controls were randomly selected for each case. Logistic regression was used to model the outcome risk associated with high-potency contrasted with low-potency statins dispensed at starting therapy, and during follow-up.

      Results

      Patients at whom high-potency statins were initially dispensed were more likely to be hospitalized for acute kidney injury within six months after starting treatment than those on low-potency statins (adjusted OR 1.54, 95% confidence interval 1.25–1.91). Patients receiving high-potency statins within three weeks before the outcome onset had a significant increased risk respect to those who did not receive statins during the same time-window (adjusted OR 1.45, 95% confidence interval 1.04–2.03). When follow-up was extended from 6 months to 12 months the difference was not significant anymore (adjusted OR 1.17, 95% confidence interval 0.89–1.54).

      Conclusions

      Use of high-potency statins is associated with an increased risk of acute kidney injury compared with low-potency statins in the first 6 months after starting therapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • et al.
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
        N Engl J Med. 1996; 335: 1001-1009
        • Nissen S.E.
        • Nicholls S.J.
        • Sipahi I.
        • et al.
        ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
        JAMA. 2006; 295: 1556-1565
        • Heart Protection Study Collaborative G
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Scandinavian Simvastatin Survival Study G
        Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Newman C.B.
        • Palmer G.
        • Silbershatz H.
        • Szarek M.
        Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients.
        Am J Cardiol. 2003; 92: 670-676
        • Pasternak R.C.
        • Smith S.C.
        • Bairey-Merz C.N.
        • et al.
        ACC/AHA/NHLBI clinical advisory on the use and safety of statins.
        Stroke. 2002; 33: 2337-2341
        • Kiortsis D.N.
        • Filippatos T.D.
        • Mikhailidis D.P.
        • Elisaf M.S.
        • Liberopoulos E.N.
        Statin-associated adverse effects beyond muscle and liver toxicity.
        Atherosclerosis. 2007; 195: 7-16
        • Wolfe S.M.
        Dangers of rosuvastatin identified before and after FDA approval.
        Lancet. 2004; 363: 2189-2190
        • Hippisley-Cox J.
        • Coupland C.
        Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database.
        BMJ. 2010; 340: c2197
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • et al.
        JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Roberts M.D.
        CRESTOR (Rosuvastatin calcium) NDA 21–366 JUPITER.
        United States Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee, 2009
        • Chung Y.-H.
        • Lee Y.-C.
        • Chang C.-H.
        • Lin M.-S.
        • Lin J.-W.
        • Lai M.-S.
        Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure.
        Pharmacoepidemiol Drug Saf. 2013; 22: 583-592
        • Dormuth C.R.
        • Brenda B.R.
        • Paterson J.M.
        • et al.
        Use of high-potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
        BMJ. 2013; 346: f880https://doi.org/10.1136/bmj.f880
        • Corrao G.
        • Cesana G.
        • Merlino L.
        Pharmacoepidemiological research and the linking of electronic healthcare databases available in the Italian region of Lombardy.
        Biomed Statistics Clin Epidemiology. 2008; 2: 117-125
        • Essebag V.
        • Platt R.W.
        • Abrahamowicz M.
        • et al.
        Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure.
        BMC Med Res Methodol. 2005; 5 (Available from:): 5
        • Law M.R.
        • Wald N.J.
        • Rudnicka A.R.
        Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.
        BMJ. 2003; 326: 1423
        • Charlson M.E.
        • Charlson R.E.
        • Peterson J.C.
        • Marinopoulos S.S.
        • Briggs W.M.
        • Hollenberg J.P.
        The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients.
        J Clin Epidemiol. 2008; 61: 1234-1240
        • Tamim H.
        • Monfared A.A.
        • LeLorier J.
        Application of lag-time into exposure definitions to control for protopathic bias.
        Pharmacoepidemiol Drug Saf. 2007; 16: 250-258
        • Murugan R.
        • Weissfeld L.
        • Yende S.
        • Singbartl K.
        • Angus D.C.
        • Kellum J.A.
        • Genetic and Inflammatory Markers of Sepsis (GenIMS) Investigators
        Association of statin use with risk and outcome of acute kidney injury in community-acquired pneumonia.
        Clin J Am Soc Nephrol. 2012; 7: 895-905
        • McMurray J.J.
        • Dunselman P.
        • Wedel H.
        • et al.
        • CORONA Study Group
        Coenzyme Q10, rosuvastatin, and clinical endpoints in heart failure: a pre-specified sub study of CORONA (controlled rosuvastatin multinational study in heart failure).
        J Am Coll Cardiol. 2010; 56: 1196-1204
        • Singh R.B.
        • Khanna H.K.
        • Niaz M.A.
        Randomized, double-blind placebo-controlled trial of coenzyme Q10 in chronic renal failure: discovery of a new role.
        J Nutr Environ Med. 2000; 10: 281-288
        • Ishikawa A.
        • Kawarazaki H.
        • Ando K.
        • Fujita M.
        • Fujita T.
        • Homma Y.
        Renal preservation effect of ubiquinol, the reduced form of coenzyme Q10.
        Clin Exp Nephrol. 2011; 15: 30-33
        • Alsheikh-Ali A.A.
        • Ambrose M.S.
        • Kuvin J.T.
        • Karas R.H.
        The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.
        Circulation. 2005; 111: 3051-3057
        • Kostapanos M.S.
        • Milionis H.J.
        • Saougos V.G.
        • et al.
        Dose-dependent effect of rosuvastatin treatment on urinary protein excretion.
        J Cardiovasc Pharmacol Ther. 2007; 12: 292-297
        • Campese V.M.
        • Ku E.
        • Bigazzi R.
        • Bianchi S.
        Do HMG-CoA reductase inhibitors improve kidney function? The saga continues.
        J Nephrol. 2011; 24: 550-553
        • Szummer K.
        • Lundman P.
        • Jacobson S.H.
        • et al.
        Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction.
        Kidney Int. 2011; 79: 997-1004
        • García-Rodríguez L.A.
        • Massó-González E.L.
        • Wallander M.-A.
        • Johansson S.
        The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care.
        Pharmacoepidemiol Drug Saf. 2008; 17: 943-952
        • Sattar N.
        • Preiss D.
        • Murray H.M.
        • et al.
        Statins and the risk of incident diabetes: a collaborative meta-analysis of randomized statin trials.
        Lancet. 2010; 375: 735-742
        • Cholesterol Treatment Trialists' (CTT) Collaborators
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681
        • Preiss D.
        • Seshasai S.R.K.
        • Welsh P.
        • et al.
        Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy.
        JAMA. 2011; 305: 2556-2564
        • Sniderman A.
        • Thanassoulis G.
        • Couture P.
        • Williams K.
        • Alam A.
        • Furberg C.D.
        Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering.
        J Clin Lipidol. 2012; 6: 303-309
        • Strom B.L.
        Overview of automated databases in pharmacoepidemiology.
        in: Strom B.L. Pharmacoepidemiology. 3rd ed. Wiley, Chichester, UK2000: 219-222
        • Ray W.A.
        Evaluating medication effects outside of clinical trials: new-user designs.
        Am J Epidemiol. 2003; 158: 915-920
        • Schneeweiss S.
        • Gagne J.J.
        • Glynn R.J.
        Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development.
        Clin Pharmacol Ther. 2011; 90: 777-790
        • Stürmer T.
        • Funk M.J.
        • Poole C.
        • Brookhart M.A.
        Nonexperimental comparative effectiveness research using linked healthcare databases.
        Epidemiology. 2011; 22: 298-301
        • Vlasschaert M.E.
        • Bejaimal S.A.
        • Hackam D.G.
        • et al.
        Validity of administrative database coding for kidney disease: a systematic review.
        Am J Kidney Dis. 2011; 57: 29-43
        • Schneeweiss S.
        • Avorn J.
        A review of uses of health care utilization databases for epidemiologic research on therapeutics.
        J Clin Epidemiol. 2005; 58: 323-337
        • Stone N.J.
        • Robinson J.
        • Lichtenstein A.H.
        • et al.
        ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013 Nov 7;